ATE461216T1 - Humaner verstärker der viralen infektion (sevi) und seine anwendung - Google Patents

Humaner verstärker der viralen infektion (sevi) und seine anwendung

Info

Publication number
ATE461216T1
ATE461216T1 AT07712110T AT07712110T ATE461216T1 AT E461216 T1 ATE461216 T1 AT E461216T1 AT 07712110 T AT07712110 T AT 07712110T AT 07712110 T AT07712110 T AT 07712110T AT E461216 T1 ATE461216 T1 AT E461216T1
Authority
AT
Austria
Prior art keywords
sevi
amplifier
application
viral infection
human viral
Prior art date
Application number
AT07712110T
Other languages
English (en)
Inventor
Ludger Staendker
Wolf-Georg Forssmann
Knut Adermann
Jan Muench
Frank Kirchhoff
Elke Ruecker
Original Assignee
Viro Pharmaceuticals Gmbh & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viro Pharmaceuticals Gmbh & Co filed Critical Viro Pharmaceuticals Gmbh & Co
Application granted granted Critical
Publication of ATE461216T1 publication Critical patent/ATE461216T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT07712110T 2006-01-25 2007-01-25 Humaner verstärker der viralen infektion (sevi) und seine anwendung ATE461216T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06100818 2006-01-25
PCT/EP2007/050727 WO2007085630A1 (en) 2006-01-25 2007-01-25 Human semen enhancer of viral infection peptides (sevi) and their use

Publications (1)

Publication Number Publication Date
ATE461216T1 true ATE461216T1 (de) 2010-04-15

Family

ID=36423519

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07712110T ATE461216T1 (de) 2006-01-25 2007-01-25 Humaner verstärker der viralen infektion (sevi) und seine anwendung

Country Status (7)

Country Link
US (1) US8299031B2 (de)
EP (1) EP1981906B1 (de)
JP (1) JP2009524420A (de)
AT (1) ATE461216T1 (de)
DE (1) DE602007005354D1 (de)
DK (1) DK1981906T3 (de)
WO (1) WO2007085630A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2071024A1 (de) * 2007-12-14 2009-06-17 Pharis Biotec GmbH Peptide der humanen prostataspezifischen sauren Phosphatase zur Erhöhung der Infektivität von Viren
US10596264B2 (en) 2011-06-30 2020-03-24 Genethon Peptides with viral infection enhancing properties and their use
CN108977412A (zh) 2012-01-26 2018-12-11 生命科技公司 用于提高病毒感染性的方法
WO2022004707A1 (ja) * 2020-06-30 2022-01-06 国立大学法人大阪大学 ＳＡＲＳ－ＣｏＶ－２吸着担体およびそれを含むカラム
EP4067375A1 (de) * 2021-03-30 2022-10-05 Universität Ulm Fibrillenformende peptide
CN115708506B (zh) * 2022-11-14 2024-01-26 海南大学 一种马氏珠母贝精子低温保存方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
EP1455816A4 (de) * 2000-10-19 2007-03-28 Epimmune Inc Hla-klasse-i- und -ii-bindende peptide und deren verwendung
GB0406054D0 (en) * 2004-03-17 2004-04-21 Univ Nottingham Trent Prostatic acid phosphatase antigens

Also Published As

Publication number Publication date
US20090191206A1 (en) 2009-07-30
JP2009524420A (ja) 2009-07-02
DE602007005354D1 (de) 2010-04-29
EP1981906A1 (de) 2008-10-22
WO2007085630A1 (en) 2007-08-02
DK1981906T3 (da) 2011-01-10
EP1981906B1 (de) 2010-03-17
US8299031B2 (en) 2012-10-30
HK1125386A1 (en) 2009-08-07

Similar Documents

Publication Publication Date Title
EA201200277A1 (ru) Антитела против респираторного синцитиального вируса (pcb) и способы их применения
EA201300125A1 (ru) Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний желудочно-кишечного тракта функциональной этиологии
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
ATE461216T1 (de) Humaner verstärker der viralen infektion (sevi) und seine anwendung
NO20076021L (no) Antistoffer rettet mot amyloid-betapeptid og metoder som anvender de samme
EA201291243A1 (ru) Антитела против респираторно-синцитиального вируса (рсв) и способы их применения
ATE543804T1 (de) Neue verbindungen
MA31991B1 (fr) Anticorps contre le virus de la grippe et procedes pour leur utilisation
EA201201116A1 (ru) Моноклональные антитела человека, полученные из в-клеток человека и обладающие нейтрализующей активностью против вирусов гриппа а
EP2987807A3 (de) Antikörper gegen phosphoryliertes tau
EA201001691A1 (ru) Антитела к гранулоцитарно-макрофагальному колониестимулирующему фактору
DE602004028168D1 (de) Monoklonale antikörper gegen den hepatozyten-wachstumsfaktor
NO20091413L (no) WNT-antagonister og deres anvendelse i diagnostiseringen og behandlingen av WNT-medierte forstyrrelser
WO2009044273A3 (en) Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
ATE376559T1 (de) Methoden der verhinderung und behandlung der alzheimer'schen krankheit
EA201600476A1 (ru) Вариант вируса ppcc, клон кднк вируса ppcc европейского типа и их применение
EA200600735A1 (ru) Нуклеиновые кислоты, специфично связывающие биоактивный грелин
EA200700202A1 (ru) Гетероарильные соединения в качестве бетамиметиков для лечения заболеваний дыхательных путей
EA201690004A1 (ru) Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение
DK2229440T3 (da) Rekombinante elastase-proteiner og fremgangsmåder til fremstilling og anvendelse deraf
EA200601219A1 (ru) Новые конденсированные пирролокарбазолы
NO20076405L (no) Anvendelse av 24-nor-UDCA
WO2008124176A3 (en) Soluble and membrane-anchored forms of lassa virus subunit proteins
DE502006007982D1 (de) Neue arzneimittelkombinationen zur behandlung von atemwegserkrankungen
DE502006008804D1 (de) Neue, langwirksame betamimetika zur behandlung von atemwegserkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties